Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • China,  Common Knowledge,  Court Cases,  Courts,  Inventiveness,  Patent,  Supreme People's Court,  Top 10 IP Case

    Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed

    August 14, 2026

    A Case Study of the “Electronic Blackboard” Case, (2025) SPC Zhi Xing Zhong No. 286 I. Introduction In assessing inventive step for invention patents, determining whether a technical solution would have been “readily conceivable” to a person skilled in the art has long been one of the most disputed and uncertain aspects of the analysis. In practice, Examiners far too often have a flawed tendency to deem a technical means a “conventional choice” in the art simply because the prior art discloses a similar function or means. This leads to Examiners directly concluding that the claim lacks inventive step as a whole. This approach suffers from two major defects: This…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Aug 14, 2026 Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed
  • Jul 21, 2026 Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments
  • Jul 14, 2026 Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics
  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard

Categories

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Aug 14, 2026 Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed
  • Jul 21, 2026 Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments
  • Jul 14, 2026 Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics
  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard
  • May 22, 2026 Breaking: China Released Drug Trial Data Protection Implementation Measures
  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
© 2026 Eagle IP Limited
Savona Theme by Optima Themes